 This is a multi-center, open label, pilot futility clinical trial of the safety, tolerability, pharmacodynamics and preliminary efficacy of oral salsalate in up to 10 patients with PSP. All participants will be administered 2,250 mg daily 1,500 mg every day before noon every AM and 750 mg every night at bedtime every HS for 6 months. 